Meeder Asset Management Inc. Boosts Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Meeder Asset Management Inc. increased its position in Zoetis Inc. (NYSE:ZTS) by 175.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,170 shares of the company’s stock after buying an additional 19,846 shares during the quarter. Meeder Asset Management Inc.’s holdings in Zoetis were worth $5,404,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of ZTS. Webster Bank N. A. increased its stake in shares of Zoetis by 89.1% in the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Private Wealth Management Group LLC purchased a new stake in Zoetis during the fourth quarter valued at approximately $33,000. Neo Ivy Capital Management bought a new stake in Zoetis during the fourth quarter valued at about $40,000. LRI Investments LLC purchased a new stake in shares of Zoetis in the first quarter worth $43,000. Finally, Blue Bell Private Wealth Management LLC increased its stake in Zoetis by 111.6% in the 1st quarter. Blue Bell Private Wealth Management LLC now owns 273 shares of the company’s stock worth $46,000 after buying an additional 144 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Performance

ZTS stock opened at $190.71 on Friday. The firm has a 50-day simple moving average of $182.52 and a two-hundred day simple moving average of $174.54. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The firm has a market cap of $86.40 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 2.91 and a beta of 0.88.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the prior year, the company posted $1.41 earnings per share. Zoetis’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities analysts forecast that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ZTS. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 price target on shares of Zoetis in a research note on Tuesday, August 27th. Finally, Piper Sandler increased their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.